Healthcare Reform
Our work in Healthcare Reform
-
Medical Device Regulation and Reimbursement: What the Pandemic Revealed
Join Schaeffer Center for a discussion on the challenges and opportunities facing the FDA and CMS in an age of breakthrough medical devices.
-
Medicare Coverage of Innovative Technologies: The U.S. Should do More to Speed Entry of Breakthrough Devices to Market
Equally pressing to FDA approval is the need to secure coverage from Medicare and Medicaid.
Categorized in -
Federal Government Should Advise on Drug Negotiations, Not Run Them
Schaeffer Center experts Karen Mulligan and Darius Lakdawalla argue that the Department of Health and Human Services should help advice drug price negotiations instead of running them.
Categorized in -
Changes in Emergency Physician Service Prices After Connecticut’s 2016 Surprise Billing Law
On January 1, 2022, the No Surprises Act will take effect. This study aims to fill that knowledge gap by presenting preliminary evidence about the effects of Connecticut’s 2016 surprise billing law on the emergency physician services market.
Categorized in -
Setting the Stage for the Next 10 Years of Health Care Payment Innovation
Nonresident Senior Fellow Bob Kocher describes four health policy strategies that could unlock large improvements in healthcare cost and quantity.
Categorized in -
Comments On a CMS Proposal to Allow Year-Round Marketplace Enrollment for Low-Income People
Schaeffer Initiative expert Matthew Fiedler provided comments to the Centers for Medicare and Medicaid Services on proposed rule that would permit people with incomes below 150% of the federal poverty level (FPL) to enroll in coverage through the Health Insurance Marketplaces established by the Affordable Care Act at any time during the year, rather than solely during the annual open enrollment period.
Categorized in -
Drug Rebates in Medicare Part D
On July 27, the USC-Brookings Schaeffer Initiative for Health Policy will host a webinar to discuss how the increasing reliance on rebates burdens many Medicare patients and policy solutions.
Categorized in -
Comparison of Spending on Common Generic Drugs by Medicare vs Costco Members
A new Schaeffer Center study comparing Medicare Part D prescription drug prices with those paid by Costco members finds that the federal government overpaid on roughly half of the most common generic medicines in 2018.
Categorized in -
USC Research Shows Costco Beats Medicare in Generic Drug Savings Nearly 50% of the Time
Intermediaries negotiate good prices, but lack incentives to pass savings to beneficiaries and taxpayers.
Categorized in -
A Medical Moonshot Would Help Fix Inequality in American Healthcare
New medical interventions can serve as a great leveler and help change the trajectory of health disparities in the United States.
Categorized in